Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

2.4K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.4K
Atypical Pneumonia01:14

Atypical Pneumonia

79
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
79
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

1.8K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
1.8K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

2.1K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.1K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.7K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.7K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.7K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma CXCL13 and fibrosis biomarkers in COVID-19 compared with idiopathic pulmonary fibrosis.

Scientific reports·2026
Same author

Occupational category, job type, and sarcoidosis: Findings from a French multicenter study.

Pulmonology·2026
Same author

Immunological efficacy and safety of influenza vaccination in adults with sarcoidosis: the SARCOVAC study.

Vaccine·2026
Same author

Aspergillosis complicating idiopathic lung fibrosis: a multicentric series.

Respiratory medicine·2026
Same author

Design of PROGRESSION-IPF: A pragmatic, open-label, randomized trial of patients with progressive disease in idiopathic pulmonary fibrosis.

Respiratory medicine and research·2026
Same author

Efficacy and safety of danazol for pulmonary fibrosis or bone-marrow failure associated with telomere-related gene mutation.

ERJ open research·2026

Related Experiment Video

Updated: Apr 26, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

22.1K

Advanced pulmonary sarcoidosis.

Dominique Valeyre1, Hilario Nunes, Jean-François Bernaudin

  • 1aAP-HP, Hôpital Avicenne, Service de Pneumologie bUniversité Paris 13, EA2363, Sorbonne Paris Cité, Bobigny cAPHP, Laboratoire d'anatomie et cytologie pathologique, Hôpital Tenon dDépartement d'histologie, Université Pierre et Marie Curie Paris 6, Paris, France.

Current Opinion in Pulmonary Medicine
|July 22, 2014
PubMed
Summary

Advanced pulmonary sarcoidosis (APS) involves fibrocystic lung lesions and distinct patterns. Serial spirometry is key for monitoring, and a new algorithm predicts survival in this complex condition.

More Related Videos

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

914
The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

9.8K

Related Experiment Videos

Last Updated: Apr 26, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

22.1K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

914
The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

9.8K

Area of Science:

  • Pulmonology
  • Radiology
  • Pathology

Background:

  • Advanced pulmonary sarcoidosis (APS) presents unique challenges in diagnosis and management.
  • Understanding its distinct pathological patterns is crucial for patient care.

Purpose of the Study:

  • To provide an updated review of recent advancements in understanding and managing advanced pulmonary sarcoidosis (APS).

Main Methods:

  • Review of current literature on APS pathology, imaging, and monitoring techniques.
  • Analysis of diagnostic criteria and prognostic indicators for APS.
  • Evaluation of emerging treatment strategies and their outcomes.

Main Results:

  • Fibrosing pulmonary sarcoidosis and usual interstitial pneumonia (UIP) differences are clarified.
  • Serial spirometry is the most reliable monitoring tool.
  • An integrative algorithm combining pulmonary function and CT scans predicts survival.

Conclusions:

  • APS is characterized by fibrocystic lesions with two main patterns, differing from UIP.
  • Active disease is common, with increased risks of respiratory insufficiency, pulmonary hypertension, and infections.
  • While treatment guidelines are lacking, antisarcoidosis therapies are often necessary, and pulmonary hypertension treatments are under evaluation.